Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair (EVAR) Using Ovation Abdominal Stent Graft Systems

Endologix Inc. announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and registries studying polymer endovascular aneurysm repair (Polymer EVAR) using Ovation® Abdominal Stent Graft Systems.

IRVINE, Calif.--(BUSINESS WIRE)-- Endologix Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced the first results from ENCORE, a pooled, global analysis of several prospective clinical trials and registries studying polymer endovascular aneurysm repair (Polymer EVAR) using Ovation® Abdominal Stent Graft Systems.

ENCORE is a pooled, retrospective analysis of six prospectively enrolled clinical trials and registries of Ovation Abdominal Stent Graft Systems encompassing 1,296 patients, 160 centers and 339 investigators in the U.S., Europe and Latin America. This contemporary analysis standardizes outcome variables across each study. The data is a mix of real world registry and controlled data, and all endpoints are presented using Kaplan-Meier survival estimates.

Median follow up across all studies was 883 days (range 30 days – 5 years). At five years, the ENCORE analysis included the following results for Ovation based on the available data:

  • 99.1% freedom from AAA-related mortality
  • 99.0% freedom from reintervention for Type 1a endoleak
  • 99.7% freedom from rupture
  • 99.2% freedom from conversion
  • 96.4% freedom from all device-related reintervention

“With ENCORE, our objective was to conduct a rigorous, global evaluation of the available Polymer EVAR clinical data, which includes nearly 1,300 patients, and to share the consolidated results with physicians worldwide,” said Matt Thompson, M.D., Chief Medical Officer for Endologix. “We look forward to sharing additional analyses from the ENCORE data set in the future, and we’d like to thank all of the clinical investigators who participated in the underlying studies that are the basis for the ENCORE analysis.”

Conference Call

The Company will host a conference call at 8:30 a.m. ET on Tuesday, March 20, 2018 to discuss the information contained in this press release and answer questions related to the ENCORE analysis. To participate in the conference call, dial 888-394-8218 (domestic) or 323-794-2149 (international).

The conference call will also be webcast and can be accessed from the "Investors" section of the Company's website at www.endologix.com. The webcast replay of the call will be available at the same site, approximately one hour after the end of the call.

A recording of the call will also be available from 11:30 a.m. ET on Tuesday, March 20, 2018, until 11:59 p.m. ET on Tuesday, March 27, 2018. To hear this recording, dial 844-512-2921 (domestic) or 412-317-6671 (international) and enter the passcode 2955995.

MORE ON THIS TOPIC